67 related articles for article (PubMed ID: 31544536)
1. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
2. Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Ravichandran S; Cohen OC; Law S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Hawkins PN; Wechalekar AD
Blood Cancer J; 2021 Jun; 11(6):118. PubMed ID: 34155191
[TBL] [Abstract][Full Text] [Related]
3. Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis.
Lopedote P; Evans B; Marchetti A; Chen T; Moscvin M; Boullt S; Bolli N; Bianchi G
Blood Adv; 2024 Apr; ():. PubMed ID: 38652890
[TBL] [Abstract][Full Text] [Related]
4. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression.
Basset M; Hummedah K; Kimmich C; Veelken K; Dittrich T; Brandelik S; Kreuter M; Hassel J; Bosch N; Stuhlmann-Laeisz C; Blank N; Müller-Tidow C; Röcken C; Hegenbart U; Schönland S
Am J Hematol; 2020 Oct; 95(10):1158-1169. PubMed ID: 32602121
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
Muchtar E; Gertz MA; Kourelis TV; Sidana S; Go RS; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Lisa Hwa Y; Gonsalves W; Warsame R; Russell S; Lust JA; Lin Y; Zeldenrust S; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Leukemia; 2020 Apr; 34(4):1135-1143. PubMed ID: 31758090
[TBL] [Abstract][Full Text] [Related]
6. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
7. Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review.
Gertz MA; Dispenzieri A
JAMA; 2020 Jul; 324(1):79-89. PubMed ID: 32633805
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Warsame R; LaPlant B; Kumar SK; Laumann K; Perez Burbano G; Buadi FK; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves WI; Kourelis T; Lust J; Russell SJ; Zeldenrust S; Lin Y; Muchtar E; Go RS; Vincent Rajkumar S; Dispenzieri A
Blood Cancer J; 2020 Jan; 10(1):4. PubMed ID: 31913261
[TBL] [Abstract][Full Text] [Related]
9. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
10. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana S; Milani P; Binder M; Basset M; Tandon N; Foli A; Dispenzieri A; Gertz MA; Hayman SR; Buadi FK; Lacy MQ; Kapoor P; Leung N; Rajkumar SV; Merlini G; Palladini G; Kumar SK
Blood Cancer J; 2020 Apr; 10(4):41. PubMed ID: 32286270
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2020 Jul; 95(7):848-860. PubMed ID: 32267020
[TBL] [Abstract][Full Text] [Related]
12. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A; Arendt B; Dasari S; Kohlhagen M; Kourelis T; Kumar SK; Leung N; Muchtar E; Buadi FK; Warsame R; Kyle RA; Lacy MQ; Dingli D; Kapoor P; Gonsalves WI; Go RS; Hayman SR; Hwa YL; Fonder A; Hobbs M; Jevremovic D; Lust JA; Zeldenrust S; Russell SJ; Rajkumar SV; Gertz MA; Murray D
Blood Cancer J; 2020 Feb; 10(2):20. PubMed ID: 32098948
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
14. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S; Muchtar E; Sidiqi MH; Jevremovic D; Dispenzieri A; Gonsalves W; Buadi F; Lacy MQ; Hayman SR; Kourelis T; Kapoor P; Go RS; Warsame R; Leung N; Rajkumar SV; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2020 May; 95(5):497-502. PubMed ID: 32010993
[TBL] [Abstract][Full Text] [Related]
15. Assessment of minimal residual disease using multiparametric flow cytometry in patients with AL amyloidosis.
Staron A; Burks EJ; Lee JC; Sarosiek S; Sloan JM; Sanchorawala V
Blood Adv; 2020 Mar; 4(5):880-884. PubMed ID: 32130406
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Palladini G; Paiva B; Wechalekar A; Massa M; Milani P; Lasa M; Ravichandran S; Krsnik I; Basset M; Burgos L; Nuvolone M; Lecumberri R; Foli A; Puig N; Sesta MA; Bozzola M; Cascino P; Nevone A; Ripepi J; Berti P; Casarini S; Annibali O; Orfao A; San-Miguel J; Merlini G
Blood Cancer J; 2021 Feb; 11(2):34. PubMed ID: 33594045
[TBL] [Abstract][Full Text] [Related]
18. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X; Yu Y; Yu H; Chen M; Zhang X; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):193. PubMed ID: 38619663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
